Miltenyi Biotec Acquires lino Biotech

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Calibre Scientific Acquires LINARIS Biologische Produkte GmbH

June 14, 2021

Healthcare Services

Calibre Scientific has acquired LINARIS Biologische Produkte GmbH, a Germany-based life-science distributor, and will integrate it with BIOZOL Diagnostica GmbH to expand product offerings and sales reach in the DACH region. The deal brings LINARIS’s supplier relationships and technical expertise into Calibre’s BIOZOL platform to strengthen its position in the German research and diagnostics market.

Bain Capital and Cinven to Acquire Lonza Specialty Ingredients

February 8, 2021

Manufacturing

Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients (LSI), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. LSI, headquartered in Basel, Switzerland, is a global provider of specialty chemicals for microbial control with ~2,800 employees, and the consortium intends to invest in R&D, bolster production capabilities and use LSI as a platform for buy-and-build consolidation in the sector; the transaction was expected to close in H2 2021.

BioAgilytix Acquires Cambridge Biomedical

November 4, 2019

Healthcare Services

BioAgilytix, a GHO Capital portfolio company, has acquired Cambridge Biomedical, a Cambridge, Massachusetts–based clinical research organisation specializing in large-molecule bioanalysis. The deal expands BioAgilytix's laboratory capacity and capabilities (including CLIA/CAP/GLP capabilities and PCR/molecular suites), broadens its geographic footprint into the Boston/Cambridge biotech cluster, and strengthens its cell- and gene-therapy bioanalytical offerings.

Lonza AG Acquires PharmaCell BV

June 1, 2017

Biotechnology

Lonza AG has completed the acquisition of PharmaCell BV, a leading European contract manufacturer of cell and gene therapies with facilities in Maastricht and Sittard-Geleen. The deal expands Lonza's autologous cell-therapy manufacturing capabilities in Europe and integrates PharmaCell's GMP production capacity and experienced team into Lonza's global CDMO network.